Skip to content
by Legal Desire
7 January 2021

Latham & Watkins advises the underwriters in Harpoon Therapeutics Public Offering

Advising firms

Deal team

15 lawyers named
LawyerFirmSeniorityPracticeOffice
Brian Cuneo Lead Latham & Watkins LLP Partner life sciences capital markets Bay Area
John Williams Lead Latham & Watkins LLP Partner life sciences capital markets Bay Area
Michelle Lu Latham & Watkins LLP Associate life sciences capital markets Not stated
Taimi Jacobson Latham & Watkins LLP Associate life sciences capital markets Not stated
Melinda Vanderburg Latham & Watkins LLP Associate life sciences capital markets Not stated
Elizabeth Richards Latham & Watkins LLP Partner FDA regulatory matters Washington, DC
Barrett Tenbarge Latham & Watkins LLP Associate FDA regulatory matters Not stated
Lacey Henry Latham & Watkins LLP Associate FDA regulatory matters Not stated
Betty Pang Latham & Watkins LLP Counsel healthcare regulatory matters Bay Area
Grace Lee Latham & Watkins LLP Partner tax matters Bay Area
Gregory Conyers Latham & Watkins LLP Associate tax matters Not stated
Chris Hazuka Latham & Watkins LLP Partner technology transactions matters Bay Area
Peggy Ni Latham & Watkins LLP Associate technology transactions matters Not stated
Jay Metz Latham & Watkins LLP Partner benefits and compensation matters Bay Area
Brianna Stellpflug Latham & Watkins LLP Associate benefits and compensation matters Not stated

Stated terms

Stated value
USD 100m ($100.0 million)
What the figure measures
Issue size
Client
Not stated
Counterparties
Harpoon Therapeutics, Inc. (Issuer)